Article Menu

Export Article

More by Authors Links

Article Data

  • Views 29459
  • Dowloads 3248

Editorials

Open Access

Crying wolf in time of Corona: the strange case of ivermectin and hydroxychloroquine. Is the fear of failure withholding potential life-saving treatment from clinical use?

  • Pasquale Nardelli1
  • Alberto Zangrillo1,2
  • Gabriele Sanchini1
  • Valery V Likhvantsev3,4
  • Andrey G Yavorovskiy4
  • Carolina Soledad Romero Garcia5
  • Giovanni Landoni1,2

1Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy

2Vita-Salute San Raffaele University, Milan, Italy

3Federal Research and Clinical Center of Resuscitation and Rehabilitation, Moscow, Russia

4IM Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia

5Department of Anaesthesia and Critical Care, Consorcio Hospital General Universitario de Valencia, Valencia, Spain

DOI: 10.22514/sv.2021.043 Vol.17,Issue 3,May 2021 pp.3-4

Submitted: 26 February 2021 Accepted: 01 March 2021

Published: 08 May 2021

*Corresponding Author(s): Giovanni Landoni E-mail: landoni.giovanni@hsr.it

PDF (241.72 kB) View Full-text

Cite and Share

Pasquale Nardelli,Alberto Zangrillo,Gabriele Sanchini,Valery V Likhvantsev,Andrey G Yavorovskiy,Carolina Soledad Romero Garcia,Giovanni Landoni. Crying wolf in time of Corona: the strange case of ivermectin and hydroxychloroquine. Is the fear of failure withholding potential life-saving treatment from clinical use?. Signa Vitae. 2021. 17(3);3-4.

URL:

https://www.signavitae.com/articles/10.22514/sv.2021.043

References

[1] Horby P, Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR, et al. Effect of hydroxychloroquine in hospitalized patients with Covid-19. New England Journal of Medicine. 2020; 383: 2030-2040.

[2] Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020; 396: 1345-1352.

[3] Furtado RHM, Berwanger O, Fonseca HA, Corrêa TD, Ferraz LR, Lapa MG, et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet. 2020; 396: 959-967.

[4] Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Research. 2020; 178: 104787.

[5] Bove T, Belletti A, Putzu A, Pappacena S, Denaro G, Landoni G, et al. Intermittent furosemide administration in patients with or at risk for acute kidney injury: Meta-analysis of randomized trials. PLoS ONE. 2018; 13: e0196088.

[6] Stauffer WM, Alpern JD, Walker PF. COVID-19 and Dexamethasone. Journal of the American Medical Association. 2020; 324: 623.


Abstracted / indexed in

Science Citation Index Expanded (SCIE) (On Hold)

Chemical Abstracts Service Source Index

Scopus: CiteScore 1.3 (2024)

Embase

Submission Turnaround Time

Top